TyRx Pharma raises $25 million
Proceeds Will Support Commercialization of the AIGISrx™ CRMD AntiBacterial Envelope and Development and Launch of Additional Drug-Eluting Devices in the TyRx Pipeline
Monmouth Junction, NJ, (February 27, 2008) — TyRx Pharma, Inc., a leader in the commercialization of implantable combination drug-device products, announced today that the Company has raised $25 million in a venture capital financing led by Clarus Ventures and co-led by Pappas Ventures. In connection with the financing, Jeffrey Leiden, M.D., Ph.D., Managing Director, and Scott Requadt, J.D., MBA, Principal, both of Clarus Ventures, and Arthur Pappas, Managing Partner, Pappas Ventures, will join TyRx’s Board of Directors.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.